257 related articles for article (PubMed ID: 20040392)
41. SOX4 is associated with poor prognosis in cholangiocarcinoma.
Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor receptor expression and gene copy number in sinonasal intestinal type adenocarcinoma.
Franchi A; Fondi C; Paglierani M; Pepi M; Gallo O; Santucci M
Oral Oncol; 2009 Sep; 45(9):835-8. PubMed ID: 19213595
[TBL] [Abstract][Full Text] [Related]
43. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
[TBL] [Abstract][Full Text] [Related]
44. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.
Law LY
J Clin Oncol; 2012 Sep; 30(27):e271-3. PubMed ID: 22851567
[No Abstract] [Full Text] [Related]
45. Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours.
Lee CS; Pirdas A
Pathol Res Pract; 1995 Nov; 191(11):1087-91. PubMed ID: 8822109
[TBL] [Abstract][Full Text] [Related]
46. Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.
Marx AH; Zielinski M; Kowitz CM; Dancau AM; Thieltges S; Simon R; Choschzick M; Yekebas E; Kaifi JT; Mirlacher M; Atanackovic D; Brümmendorf TH; Fiedler W; Bokemeyer C; Izbicki JR; Sauter G
Histopathology; 2010 Sep; 57(3):418-26. PubMed ID: 20840671
[TBL] [Abstract][Full Text] [Related]
47. Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract.
Cabibi D; Licata A; Barresi E; Craxì A; Aragona F
Pathol Res Pract; 2003; 199(2):65-70. PubMed ID: 12747467
[TBL] [Abstract][Full Text] [Related]
48. Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas.
Piris A; Scopsi L; Clemente C; Cetti Serbelloni F; Mihm MC; Hoang MP
Am J Dermatopathol; 2010 Aug; 32(6):586-92. PubMed ID: 20534988
[TBL] [Abstract][Full Text] [Related]
49. Characterization of EGFR family gene aberrations in cholangiocarcinoma.
Yang X; Wang W; Wang C; Wang L; Yang M; Qi M; Su H; Sun X; Liu Z; Zhang J; Qin X; Han B
Oncol Rep; 2014 Aug; 32(2):700-8. PubMed ID: 24927194
[TBL] [Abstract][Full Text] [Related]
50. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract.
Sung JY; Kim GY; Lim SJ; Park YK; Kim YW
Pathol Res Pract; 2010 Jan; 206(1):24-9. PubMed ID: 19819644
[TBL] [Abstract][Full Text] [Related]
51. DNA image analysis study of lesions of the gallbladder and biliary system.
Brunt EM; Kraemer BB
Liver Transpl Surg; 1996 Jul; 2(4):284-9. PubMed ID: 9346662
[TBL] [Abstract][Full Text] [Related]
52. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
53. [Gallbladder and bile duct carcinoma. Biology and pathology].
Tannapfel A; Wittekind C
Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
[TBL] [Abstract][Full Text] [Related]
54. TTF-1 and Napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels.
Surrey LF; Frank R; Zhang PJ; Furth EE
Am J Surg Pathol; 2014 Feb; 38(2):224-7. PubMed ID: 24418856
[TBL] [Abstract][Full Text] [Related]
55. Adenocarcinoma with pyloric gland phenotype of the extrahepatic bile ducts: a previously unrecognized and distinctive morphologic variant of extrahepatic bile duct carcinoma.
Albores-Saavedra J; Chablé-Montero F; Méndez-Sánchez N; Mercado MÁ; Vilatoba-Chapa M; Henson DE
Hum Pathol; 2012 Dec; 43(12):2292-8. PubMed ID: 22795356
[TBL] [Abstract][Full Text] [Related]
56. Regulators of apoptosis in cholangiocarcinoma.
Jhala NC; Vickers SM; Argani P; McDonald JM
Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670
[TBL] [Abstract][Full Text] [Related]
57. Clinical significance of nucleophosmin/B23 and human epidermal growth factor receptor 2/neu expressions in gastric cancers.
Zhou F; Qiu W; Sun L; Xiang J; Sun X; Sui A; Ding A; Yue L
APMIS; 2013 Jul; 121(7):582-91. PubMed ID: 23489260
[TBL] [Abstract][Full Text] [Related]
58. Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma.
de Pinieux G; Colin D; Vincent-Salomon A; Couturier J; Amsellem-Ouazana D; Beuzeboc P; Vieillefond A
Virchows Arch; 2004 May; 444(5):415-9. PubMed ID: 15029496
[TBL] [Abstract][Full Text] [Related]
59. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts.
Washington K; Gottfried MR
Liver; 1996 Apr; 16(2):99-104. PubMed ID: 8740842
[TBL] [Abstract][Full Text] [Related]
60. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
